Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Global study reviews brain metastasis treatments in colorectal cancer patients

NCT ID NCT07448662

Knowledge-focused Sponsor: Blokhin's Russian Cancer Research Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study looks back at 700 patients from 15 hospitals in 2 countries to compare local treatments like surgery and radiation for brain metastases that spread from colorectal cancer. Researchers will track how long patients live and how long it takes for brain tumors to progress after treatment. The goal is to understand which strategies work best in real-world practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors choose the best local treatment (surgery or radiation) for brain metastases from colorectal cancer, potentially improving survival and quality of life.
What could go wrong
This is a retrospective observational study, not a controlled trial, so results may be influenced by patient selection and differences in care. It cannot prove one treatment is better than another.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

700 people

The number who actually took part.

Started

Feb 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients (≥ 18 years) with histologically confirmed colorectal adenocarcinoma and radiologically ± histologically documented brain metastases. Patients with synchronous or metachronous multiple primary tumors confined to the colon or rectum are eligible. Patients referred after initial local treatment for brain metastases are included provided that complete documentation of the first treatment modality is available.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female patients aged 18 years or older; * Histologically confirmed epithelial malignancy of the colon or rectum (colorectal adenocarcinoma). Patients with synchronous or metachronous multiple primary tumors within the colon or rectum are eligible; * Radiologically ± histologically confirmed brain metastases, including: * Solid brain parenchymal metastases * Leptomeningeal disease (LMD) * Both solid metastases and LMD Exclusion Criteria: * Synchronous or metachronous multiple primary malignancies (MPM) involving sites other than the colon or rectum * Primary tumor located outside the gastrointestinal tract; * Histologically confirmed non-epithelial gastrointestinal malignancy (e.g., neuroendocrine tumors, sarcoma, gastrointestinal stromal tumor, lymphoma); * Isolated spinal cord involvement without brain parenchymal metastases; * Incomplete medical records precluding assessment of at least one primary endpoint (OS, TTIP, or CNS-PFS). Patients with available data for any primary endpoint are eligible, even if other clinical details are missing. * Prior local treatment for brain metastases at an outside institution with no available records, precluding determination of the first local treatment modality

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer colonic neoplasm colorectal adenocarcinoma colorectal cancer colorectal neoplasm metastatic malignant neoplasm in the brain rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain metastases, adult Colorectal cancer

Contacts and locations

Locations

  • A.S. Loginov Moscow Clinical Scientific Center

    Moscow, 111123, Russia

  • Blokhin's Russian Cancer Research Center

    Moscow, 115478, Russia

  • Federal Center of Neurosurgery

    Tyumen, 625062, Russia

  • Gamma Knife Center Moscow

    Moscow, 125047, Russia

  • Gomel Regional Clinical Oncology Dispensary (OKOD)

    Homyel, 246012, Belarus

  • Kaliningrad Regional Clinical Oncology Center

    Kaliningrad, 236016, Russia

  • Moscow Multidisciplinary Clinical Center "Kommunarka"

    Moscow, 117303, Russia

  • Moscow Regional Oncology Hospital No. 62

    Krasnogorsk, 143442, Russia

  • N.N. Burdenko National Medical Research Center of Neurosurgery

    Moscow, 125047, Russia

  • N.N. Petrov National Medical Research Center of Oncology

    Saint Petersburg, 197758, Russia

  • N.V. Sklifosovsky Research Institute for Emergency Medicine

    Moscow, 129090, Russia

  • OncoStop CyberKnife Center

    Moscow, 115478, Russia

  • P.A. Hertsen Moscow Oncology Research Institute

    Moscow, 125284, Russia

  • Republican Clinical Oncology Dispensary (RCOD)

    Ufa, 450054, Russia

  • S.S. Yudin City Clinical Hospital, Oncology Center No. 1

    Moscow, 115446, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.